Phase i dose-escalation study of stereotactic body radiotherapy (SBRT) for poor surgical candidates with localized renal cell carcinoma

Keyphrases

• Dose-escalation Study 100%
• Localized Renal Cell Carcinoma 100%
• Poor Surgical Candidates 100%
• Stereotactic Body Radiotherapy 100%
• Dose-limiting Toxicity 66%
• Median Range 66%
• Treatment-related 66%
• Duodenal Ulcer 66%
• Response Evaluation Criteria in Solid Tumors (RECIST) 66%
• Experimental Therapeutics 33%
• In(III) 33%
• Adverse Events 33%
• Acute Toxicity 33%
• Escalating Dose 33%
• Dose Escalation 33%
• Partial Response 33%
• Urinary Incontinence 33%
• Renal Cell Carcinoma 33%
• Tolerability 33%
• Phase I Trial 33%
• Imaging Results 33%
• Karnofsky Performance Status 33%
• Tumor Response 33%
• Comorbid Conditions 33%
• Tumor Volume 33%
• Stable Disease 33%
• Patients Included 33%
• Chronic Kidney Disease 33%
• Gastrointestinal 33%
• Tumor Measurement 33%
• Initial Biopsy 33%
• Percutaneous Biopsy 33%
• Renal Toxicity 33%
• Late Toxicity 33%
• Pelvic Radiotherapy 33%
• Abdominal Radiotherapy 33%
• Genitourinary Toxicity 33%
• Common Terminology Criteria 33%

Medicine and Dentistry

• Clear Cell Renal Cell Carcinoma 100%
• Biopsy Technique 100%
• Stereotactic Body Radiation Therapy 100%
• Neoplasm 66%
• Duodenum Ulcer 66%
• Response Evaluation Criteria in Solid Tumors 66%
• Adverse Event 33%
• Urine Incontinence 33%
• Chronic Kidney Disease 33%
• Nephrotoxicity 33%
• Acute Toxicity 33%
• Karnofsky Performance Status 33%
• Percutaneous Biopsy 33%
• Phase I Trials 33%
• Experimental Therapy 33%
• Pelvic Radiotherapy 33%
• Diseases 33%
• Enuresis 33%